Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03997383 · ClinicalTrials.gov registry record · Phase 3
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
A Phase 3 study of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, sponsored by Alnylam Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT03997383 is a Phase 3 study of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy that is active but no longer recruiting, run by Alnylam Pharmaceuticals. The registered enrollment target is 360 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT03997383, a Phase 3 study of Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, is active but no longer recruiting, sponsored by Alnylam Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Patisiran
Study Locations (20)
Pennsylvania
- Clinical Trial Site - Philadelphia
- Clinical Trial Site - Philadelphia
- Clinical Trial Site - Pittsburgh
Illinois
- Clinical Trial Site - Chicago
- Clinical Trial Site - Skokie
Massachusetts
- Clinical Trial Site - Boston
- Clinical Trial Site - Burlington
New York
- Clinical Trial Site - New York
- Clinical Trial Site - New York
California
- Clinical Trial Site - Los Angeles
Iowa
- Clinical Trial Site - Iowa City
Kansas
- Clinical Trial Site - Kansas City
Maryland
- Clinical Trial Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2019-09-12 |
| Est. Completion | 2027-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03997383
The ClinicalTrials.gov registry entry for NCT03997383 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transthyretin Amyloidosis (ATTR) With Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03997383 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Pennsylvania, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03997383 about?
NCT03997383 is a clinical study titled "APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)". The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.
What is the current status of trial NCT03997383?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2019-09-12. Estimated completion is 2027-03-15.
What conditions does trial NCT03997383 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy.
What interventions are being tested in trial NCT03997383?
The interventions under investigation include: Placebo (DRUG), Patisiran (DRUG).
Who is sponsoring clinical trial NCT03997383?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03997383 being conducted?
This trial has 20 study locations across California, Illinois, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.